{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/JAZZ/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-09T13:23:02.548Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8780,"canonical_name":"Jazz Pharmaceuticals plc","cik":"0001232524","uei":null,"lei":null,"duns":null,"ticker":"JAZZ"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35,"clinical":9},"count":44,"timeline":[{"ts":"2026-07-14","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Jazz Pharmaceuticals plc — 2026-07-14","url_slug":"/sec/cik-0001232524/defa14a/0001628280-26-048166","accession_number":"0001628280-26-048166","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-07-02","url_slug":"/sec/cik-0001232524/4/0001607737-26-000011","accession_number":"0001607737-26-000011","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-07-02","url_slug":"/sec/cik-0001232524/4/0001737329-26-000010","accession_number":"0001737329-26-000010","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-07-02","url_slug":"/sec/cik-0001232524/4/0001783908-26-000019","accession_number":"0001783908-26-000019","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-07-02","url_slug":"/sec/cik-0001232524/4/0001805688-26-000012","accession_number":"0001805688-26-000012","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-07-02","url_slug":"/sec/cik-0001232524/4/0002013156-26-000007","accession_number":"0002013156-26-000007","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Bruce C Cozadd","title":"Officer","shares":6000,"usd_value":1442820,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001628280-26-046482","importance":40.288564},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"COZADD BRUCE C","title":null,"shares":6000,"price_per_share":240.47,"usd_value":1442820,"security_title":"Ordinary Shares","importance":36.44282},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"GALA RENEE D","title":"President & CEO","shares":4835,"price_per_share":237.72,"usd_value":1149376,"security_title":"Ordinary Shares","importance":16.1493762},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"Iannone Robert","title":"EVP, Global Head of R&D & CMO","shares":3764,"price_per_share":237.72,"usd_value":894778,"security_title":"Ordinary Shares","importance":15.89477808},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"Johnson Philip L","title":"EVP & Chief Financial Officer","shares":3343,"price_per_share":237.72,"usd_value":794698,"security_title":"Ordinary Shares","importance":15.79469796},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"Patil Neena M","title":"EVP & Chief Legal Officer","shares":2678,"price_per_share":237.72,"usd_value":636614,"security_title":"Ordinary Shares","importance":15.63661416},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"Pearce Samantha","title":"EVP, Chief Commercial Officer","shares":2527,"price_per_share":237.72,"usd_value":600718,"security_title":"Ordinary Shares","importance":15.60071844},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-17","url_slug":"/sec/cik-0001232524/4/0001756253-26-000004","accession_number":"0001756253-26-000004","importance":30},{"ts":"2026-06-15","kind":"sec.form144","reporter":"MARK D SMITH","title":"Director","shares":1157,"usd_value":266746,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006065","importance":40.05334927},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Smith Mark Douglas","title":null,"shares":1157,"price_per_share":230.55,"usd_value":266746,"security_title":"Ordinary Shares","importance":35.26674635},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — Jazz Pharmaceuticals plc — 2026-06-15","url_slug":"/sec/cik-0001232524/144/0001950047-26-006065","accession_number":"0001950047-26-006065","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-12","url_slug":"/sec/cik-0001232524/4/0001783908-26-000017","accession_number":"0001783908-26-000017","importance":30},{"ts":"2026-06-10","kind":"sec.form144","reporter":"NEENA PATIL","title":"Officer","shares":1200,"usd_value":278196,"security_title":"Common","approx_sale_date":"2026-06-10","accession_number":"0001950047-26-005852","importance":40.0556392},{"ts":"2026-06-10","kind":"sec.insider.s","reporter":"Patil Neena M","title":"EVP & Chief Legal Officer","shares":1200,"price_per_share":231.83,"usd_value":278196,"security_title":"Ordinary Shares","importance":35.278196},{"ts":"2026-06-10","kind":"sec.filing","form_type":"144","title":"144 — Jazz Pharmaceuticals plc — 2026-06-10","url_slug":"/sec/cik-0001232524/144/0001950047-26-005852","accession_number":"0001950047-26-005852","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Jazz Pharmaceuticals plc — 2026-06-08","url_slug":"/sec/cik-0001232524/def-14a/0001232524-26-000029","accession_number":"0001232524-26-000029","importance":40},{"ts":"2026-06-08","kind":"sec.filing","form_type":"ARS","title":"ARS — Jazz Pharmaceuticals plc — 2026-06-08","url_slug":"/sec/cik-0001232524/ars/0001232524-26-000031","accession_number":"0001232524-26-000031","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Jazz Pharmaceuticals plc — 2026-06-08","url_slug":"/sec/cik-0001232524/defa14a/0001232524-26-000030","accession_number":"0001232524-26-000030","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-05","url_slug":"/sec/cik-0001232524/4/0001607737-26-000008","accession_number":"0001607737-26-000008","importance":30},{"ts":"2026-06-03","kind":"sec.insider.g","reporter":"GALA RENEE D","title":"President & CEO","shares":600,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Bruce C Cozadd","title":"Officer","shares":6000,"usd_value":1410720,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001628280-26-039499","importance":40.282144},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"COZADD BRUCE C","title":null,"shares":6000,"price_per_share":235.12,"usd_value":1410720,"security_title":"Ordinary Shares","importance":36.41072},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-01","url_slug":"/sec/cik-0001232524/4/0001536639-26-000002","accession_number":"0001536639-26-000002","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-01","url_slug":"/sec/cik-0001232524/4/0001783908-26-000014","accession_number":"0001783908-26-000014","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Jazz Pharmaceuticals plc — 2026-06-01","url_slug":"/sec/cik-0001232524/4/0001805688-26-000008","accession_number":"0001805688-26-000008","importance":30},{"ts":"2026-05-28","kind":"sec.insider.s","reporter":"Pearce Samantha","title":"EVP, Chief Commercial Officer","shares":6907,"price_per_share":235.41,"usd_value":1625977,"security_title":"Ordinary Shares","importance":36.62597687},{"ts":"2026-05-28","kind":"sec.insider.s","reporter":"Patil Neena M","title":"EVP & Chief Legal Officer","shares":1192,"price_per_share":236.97,"usd_value":282468,"security_title":"Ordinary Shares","importance":35.28246824},{"ts":"2026-05-28","kind":"sec.insider.m","reporter":"Pearce Samantha","title":"EVP, Chief Commercial Officer","shares":6907,"price_per_share":109.45,"usd_value":755971,"security_title":"Ordinary Shares","importance":15.75597115},{"ts":"2026-05-28","kind":"sec.insider.m","reporter":"Mulligan Seamus","title":null,"shares":3415,"price_per_share":138.08,"usd_value":471543,"security_title":"Ordinary Shares","importance":15.4715432},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07233239","excerpt":"[\"Focal Seizures\"]","importance":30},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex","security_title":"PHASE4","status":"COMPLETED","accession_number":"NCT05864846","excerpt":"[\"Tuberous Sclerosis Complex Associated Neuropsychiatric Disease\"]","importance":25},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy","security_title":"PHASE4","status":"COMPLETED","accession_number":"NCT05869773","excerpt":"[\"Narcolepsy\"]","importance":25},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05557045","excerpt":"[\"Advanced Cancer\",\"Metastatic Cancer\",\"Solid Tumor\"]","importance":30},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution","security_title":"PHASE4","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05044819","excerpt":"[\"Lennox Gastaut Syndrome\",\"Dravet Syndrome\",\"Tuberous Sclerosis Complex\"]","importance":25},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07377539","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05152147","excerpt":"[\"Gastric Neoplasms\",\"Gastroesophageal Adenocarcinoma\",\"Esophageal Adenocarcinoma\"]","importance":60},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05580562","excerpt":"[\"H3 K27M\",\"Glioma\"]","importance":60},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Jazz Pharmaceuticals","title":"A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07533942","excerpt":"[\"Meningioma\"]","importance":45}]}